THE first biologic medicine to treat severe allergic asthma in certain patients will become available on the Pharmaceutical Benefits Scheme from today for children aged six years and over.
Xolair (omalizumab) from Novartis is to be initiated by a specialist.
CLICK HERE to access the PI.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Dec 16